Home › Research › Topics › fda-adverse
fda-adverse
2 studies tagged fda-adverse, dated 2025-03-13 to 2026-06-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
2 studies carry this tag.
Date range
2025 to 2026
Top journals
- Frontiers in pharmacology 2
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and compared in spontaneous reporting systems.
-
57/100
Our real-world analysis identified ARIA-related events as the primary safety concern for aducanumab, typically occurring within 146 days of treatment initiation, with comparable safety profiles across sex but heightened risks in patients ≥75 years.